Our Partners

    • NCI/SWOGthe National Cancer Institute (NCI) and SWOG, an NCI-supported clinical trials group.
    • CEPiA Sanofi – our manufacturing partner – Within the Industrial Affairs Division of Sanofi, CEPiA is an organization fully dedicated to third party CMO activities.
    • University of Arizona and University of California, Irvinewhere it all started and with whom CPP has an exclusive license agreement for key intellectual property for eflornithine plus sulindac.
    • NANT and the Children’s Hospital of LANew Approaches to Neuroblastoma Therapy is a group of 15 Universities and Children’s Hospitals with strong research and treatment programs for neuroblastoma.
    • CHOP/COGthe Children’s Hospital of Philadelphia on behalf of the Children’s Oncology Group.
    • TRAC – Translational Accelerator, LLC, a venture fund formed to invest in Arizona biotech companies, is the lead investor.